MetaVia Inc.

Aug 07, 2025

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 06, 2025

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

May 14, 2025

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 07, 2025

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

Apr 22, 2025

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Mar 20, 2025

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Jan 10, 2025

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

Dec 18, 2024

MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

Dec 02, 2024

MetaVia to Present at the Emerging Growth Conference in December